LATEST NEWSSun, 1. March 2020PROVIREX Genome Editing Therapies GmbH and Pantherna Therapeutics GmbH are developing lipid-based delivery systems for mRNA-directed genome editing of lymphocytes for the treatment of HIV and other life-threatening persistent viral diseases.
LATEST NEWSFri, 29. November 2019PROVIREX’s proprietary Brec1 technology enters clinical testing as a first-in-human phase
